US FDA Approved Alembic Pharma’s Colon Cancer Injection

The US FDA approved Alaembic Pharma’s Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) in India. Patients with colon and rectal adenocarcinomas, breast adenocarcinomas, gastric adenocarcinomas, and pancreatic adenocarcinomas are treated with the injection. Fluorouracil Infusion has an expected market size of $5 million for a considerable length of time finishing December 2022, as indicated […]

Continue Reading

Alembic Pharma Gets US FDA Tentative Approval for Acalabrutinib Capsules

Alembic Pharmaceuticals gained 1.19 percent to Rs 559 following the tentative approval of its Acalabrutinib capsules from the US Food and Drug Administration (USFDA). Calquence capsules, 100 mg, from AstraZeneca UK (AstraZeneca), the reference listed drug product (RLD), is the therapeutic equivalent of the approved ANDA. Acalabrutinib capsules are indicated for the treatment of adult […]

Continue Reading